Literatur
- 1
Adams C, Fenton M, Quraishi S, David A.
Systematic meta-review of depot antipsychotic drugs for people with schizophrenia.
Br J Psychiatry.
2001;
179
290-299
- 2 American Psychiatric Association .Practice guideline for the treatment of patients
with schizophrenia. Second edition. Washington DC: American Psychiatric Association
2004
- 3
Basan A, Leucht S.
Valproate for schizophrenia.
Cochrane Database Syst Rev.
2004;
CD004028
- 4 Benkert O, Hippius H. Kompendium der Psychiatrischen Pharmakotherapie. Berlin, Heidelberg,
New York: Springer 2003
- 5
Carpenter Jr W T, Buchanan R W, Kirkpatrick B, Breier A F.
Diazepam treatment of early signs of exacerbation in schizophrenia.
Am J Psychiatry.
1999;
156
299-303
- 6
Davis J M, Matalon L, Watanabe M D, Blake L, Metalon L.
Depot antipsychotic drugs. Place in therapy.
Drugs.
1994;
47
741-773
- 7 Deutsche Gesellschaft für Psychiatrie, Psychotherapie und Nervenheilkunde .Praxisleitlinien
in Psychiatrie und Psychotherapie. Darmstadt: Steinkopff 1998
- 8
Dolder C R, Lacro J P, Dunn L B, Jeste D V.
Antipsychotic medication adherence: is there a difference between typical and atypical
agents?.
Am J Psychiatry.
2002;
159
103-108
- 9
Gaebel W, Janner M, Frommann N, Pietzcker A, Kopcke W, Linden M, Muller P, Muller-Spahn F,
Tegeler J.
First vs multiple episode schizophrenia: two-year outcome of intermittent and maintenance
medication strategies.
Schizophr Res.
2002;
53
145-159
- 10
Gitlin M, Nuechterlein K, Subotnik K L, Ventura J, Mintz J, Fogelson D L, Bartzokis G,
Aravagiri M.
Clinical outcome following neuroleptic discontinuation in patients with remitted recent-onset
schizophrenia.
Am J Psychiatry.
2001;
158
1835-1842
- 11
Hogarty G E, Schooler N R, Ulrich R, Mussare F, Ferro P, Herron E.
Fluphenazine and social therapy in the aftercare of schizophrenic patients. Relapse
analyses of a two-year controlled study of fluphenazine decanoate and fluphenazine
hydrochloride.
Arch Gen Psychiatry.
1979;
36
1283-1294
- 12
Kane J, Honigfeld G, Singer J, Meltzer H.
Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with
chlorpromazine.
Arch Gen Psychiatry.
1988;
45
789-796
- 13
Kane J M.
Schizophrenia.
N Engl J Med.
1996;
334
34-41
- 14
Kane J M.
Strategies for improving compliance in treatment of schizophrenia by using a long-acting
formulation of an antipsychotic: clinical studies.
J Clin Psychiatry.
2003;
64
34-40
- 15
Kane J M, Eerdekens M, Lindenmayer J P, Keith S J, Lesem M, Karcher K.
Long-acting injectable risperidone: efficacy and safety of the first long-acting atypical
antipsychotic.
Am J Psychiatry.
2003;
160
1125-1132
- 16
Kane J M, Leucht S, Carpenter D, Docherty J P.
Expert consensus guideline series. Optimizing pharmacologic treatment of psychotic
disorders. Introduction: methods, commentary, and summary.
J Clin Psychiatry.
2003;
64
5-19
- 17
Keith S J, Kane J M.
Partial compliance and patient consequences in schizophrenia: our patients can do
better.
J Clin Psychiatry.
2003;
64
1308-1315
- 18
Kemp R, Kirov G, Everitt B, Hayward P, David A.
Randomised controlled trial of compliance therapy. 18-month follow-up.
Br J Psychiatry.
1998;
172
413-419
- 19
Lehman A F, Steinwachs D M.
Translating research into practice: the Schizophrenia Patient Outcomes Research Team
(PORT) treatment recommendations.
Schizophr Bull.
1998;
24
1-10
- 20
Leucht S, Barnes T R, Kissling W, Engel R R, Correll C, Kane J M.
Relapse prevention in schizophrenia with new-generation antipsychotics: a systematic
review and exploratory meta-analysis of randomized, controlled trials.
Am J Psychiatry.
2003;
160
1209-1222
- 21
Leucht S, McGrath J, White P, Kissling W.
Carbamazepine for schizophrenia and schizoaffective psychoses.
Cochrane Database Syst Rev.
2002;
CD001258
- 22
Lieberman J, Koreen A, Chakos M, Sheitman B, Woerner M, Alvir J, Bilder R.
Factors influencing treatment response and outcome of first-episode schizophrenia:
implications for understanding the pathophysiology of schizophrenia.
J Clin Psychiatry.
1996;
57
5-9
- 23
Maples N, Velligan D, DiCocco M, Castillo D, Lam Y, Ereshefsky L, Korell S, Archuleta D,
Miller A L.
Has medication adherence improved with the new-generation atypical antipsychotics?.
Schizophr Res.
2003;
60
325
- 24
Marder S R, Glynn S M, Wirshing W C, Wirshing D A, Ross D, Widmark C, Mintz J, Liberman R P,
Blair K E.
Maintenance treatment of schizophrenia with risperidone or haloperidol: 2-year outcomes.
Am J Psychiatry.
2003;
160
1405-1412
- 25
McGorry P, Killackey E, Elkins K, Lambert M, Lambert T.
Summary Australian and New Zealand clinical practice guideline for the treatment of
schizophrenia.
Australasian Psychiatry.
2003;
11
136-147
- 26
Mullen J, Jibson M, Sweitzer D.
Comparison of the relative safety, efficacy, and tolerability of quetiapine and risperidone
in outpatients with schizophrenia and other psychotic disorders: the quetiapine experience
with safety and tolerability (QUEST) study.
Clin Ther.
2003;
23
1839-1854
- 27 National Institute for Clinical Excellence (NICE) .Guidance on the use of newer
(atypical) antipsychotic drugs for the treatment of schizophrenia. Technology Appraisal
Guidance No. 43. London: National Institute for Clinical Excellence 2002
- 28
Novak-Grubic V, Tavcar R.
Predictors of noncompliance in males with first-episode schizophrenia, schizophreniform
and schizoaffective disorder.
Eur Psychiatry.
2002;
17
148-154
- 29
Oehl M, Hummer M, Fleischhacker W W.
Compliance with antipsychotic treatment.
Acta Psychiatr Scand Suppl.
2000;
102
83-86
- 30
Oosthuizen P P, Emsley R A, Maritz J S, Turner J A, Keyter N.
Incidence of tardive dyskinesia in first-episode psychosis patients treated with low-dose
haloperidol.
J Clin Psychiatry.
2003;
64
1075-1080
- 31
Perkins D O.
Predictors of noncompliance in patients with schizophrenia.
J Clin Psychiatry.
2002;
63
1121-1128
- 32
Rijcken C A, Tobi H, Vergouwen A C, de Jong-van den Berg L T.
Refill rate of antipsychotic drugs: an easy and inexpensive method to monitor patients’
compliance by using computerised pharmacy data.
Pharmacoepidemiol Drug Saf.
2004;
13
365-370
- 33
Rothbard A B, Kuno E, Foley K.
Trends in the rate and type of antipsychotic medications prescribed to persons with
schizophrenia.
Schizophr Bull.
2003;
29
531-540
- 34
Schulz S C, Thompson P A, Jacobs M, Ninan P T, Robinson D, Weiden P J, Yadalam K,
Glick I D, Odbert C L.
Lithium augmentation fails to reduce symptoms in poorly responsive schizophrenic outpatients.
J Clin Psychiatry.
1999;
60
366-372
- 35
Sernyak M J, Leslie D, Rosenheck R.
Use of system-wide outcomes monitoring data to compare the effectiveness of atypical
neuroleptic medications.
Am J Psychiatry.
2003;
160
310-315
- 36
Shiloh R, Zemishlany Z, Aizenberg D, Radwan M, Schwartz B, Dorfman-Etrog P, Modai I,
Khaikin M, Weizman A.
Sulpiride augmentation in people with schizophrenia partially responsive to clozapine.
A double-blind, placebo-controlled study.
Br J Psychiatry.
1997;
171
569-573
- 37
Tandon R, Jibson M.
Efficacy of newer generation antipsychotics in the treatment of schizophrenia.
Psychoneuroendocrinology.
2003;
28
9-26
- 38
Wahlbeck K, Cheine M, Essali M A.
Clozapine versus typical neuroleptic medication for schizophrenia.
Cochrane Database Syst Rev.
2000;
CD000059
- 39
Walburn J, Gray R, Gournay K, Quraishi S, David A S.
Systematic review of patient and nurse attitudes to depot antipsychotic medication.
Br J Psychiatry.
2001;
179
300-307
- 40
Whitehead C, Moss S, Cardno A, Lewis G.
Antidepressants for people with both schizophrenia and depression.
Cochrane Database Syst Rev.
2002;
CD002305
- 41
Wobrock T, Falkai P, Pajonk F G.
Akuttherapie der Schizophrenie.
Fortschr Neurol Psychiatr.
2004;
12
705-726
- 42
Wolkowitz O M, Pickar D.
Benzodiazepines in the treatment of schizophrenia: a review and reappraisal.
Am J Psychiatry.
1991;
148
714-726
- 43 World Health Organisation (WHO) .Schizophrenia: An international Follow-Up-Study. New
York: Wiley 1979
- 44
Zygmunt A, Olfson M, Boyer C A, Mechanic D.
Interventions to improve medication adherence in schizophrenia.
Am J Psychiatry.
2002;
159
1653-1664
Priv.-Doz. Dr. med. Frank-Gerald Pajonk
Klinik für Psychiatrie und Psychotherapie, Universitätsklinikum des Saarlandes
66421 Homburg/Saar
Email: frank.pajonk@uniklinik-saarland.de
